New Dermatology Company Resilia Pharmaceuticals Begins Operations
Specialty Pharma Company Selling Ecoza® (econazole nitrate) topical foam, 1%, Recedo® Topical Gel, Neosalus® Cream, Neosalus® Foam, and Neocera® Advanced Cream Is Focused on Patient Outcomes
News provided by
Share this article
Share this article
NEW YORK and ATLANTA, Dec. 28, 2020 /PRNewswire/ Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www.peakpharmapartners.com). announced today the creation and start of operations of Resilia Pharmaceuticals, Inc.
Resilia s product line consists of Ecoza
® (econazole nitrate) topical foam, 1%, an antifungal medicine indicated for the treatment of interdigital tinea pedis or athlete s foot; Recedo® topical gel, a leading prescription product for scar management; Neosalus